Portal and Peripheral Cortisol Levels in Obese Humans

Overview

Journal Diabetologia

Specialty Endocrinology

Date 2004 Apr 20

PMID 15095041

Citations 6

Authors

W Aldhahi

E Mun

A B Goldfine

Affiliations

Soon will be listed here.

Abstract

Aims/hypothesis: Excess total body and visceral fat has been associated with insulin resistance, diabetes and the metabolic syndrome. Excess glucocorticoids produce both central obesity and diabetes. However, systemic glucocorticoid levels are normal in typical Type 2 diabetes and persons with idiopathic obesity. Glucocorticoids can be produced locally through the enzyme 11 beta hydroxysteroid dehydrogenase type 1 (11 beta HSD-1). Transgenic mice with selective overexpression in adipose tissue of 11 beta HSD-1 to levels seen in humans develop visceral obesity, hyperlipidaemia and insulin-resistant diabetes associated with a 2.7-fold increase in corticosterone levels in portal compared to peripheral circulation. To examine whether the liver is exposed to higher levels of glucocorticoids, which may undergo metabolic degradation prior to measurement in the systemic circulation, we assessed concentrations of cortisol in the portal and peripheral circulation in morbidly obese humans.

Methods: Portal and peripheral blood samples were obtained simultaneously from six morbidly obese humans with and without diabetes during bariatric abdominal surgery. The samples were assessed for serum cortisol to determine whether an increase in the portal to peripheral circulation is found in obese humans. Insulin, which undergoes metabolic clearance in the liver, and thyroxin (free T(4)), which does not, were also assessed.

Results: Levels of serum cortisol (698.8+/-200.4 vs 696.3+/-232.4 nmol/l, portal vs peripheral, p=0.9) and free T(4) (22.0+/-7.8 vs 20.6+/-8.1 pmol/l, portal vs peripheral, p=0.3) were not significantly different in portal compared to peripheral circulation. Portal insulins were significantly higher than peripheral levels (466.7+/-302.9 vs 78.5+/-50.9 pmol/l, portal vs peripheral, p=0.03).

Conclusions/interpretation: These observations suggest that in morbidly obese humans the liver is not exposed to excess glucocorticoids.

Citing Articles

Translating PUFA omega 6:3 ratios from wild to captive hibernators (Urocitellus parryii) enhances sex-dependent mass-gain without increasing physiological stress indicators.

Mikes M, Rice S, Bibus D, Kitaysky A, Drew K J Comp Physiol B. 2022; 192(3-4):529-540.

PMID: 35503574 PMC: 9197884. DOI: 10.1007/s00360-022-01437-6.

Hypercortisolism in obesity-associated hypertension.

Varughese A, Nimkevych O, Uwaifo G Curr Hypertens Rep. 2014; 16(7):443.

PMID: 24801134 DOI: 10.1007/s11906-014-0443-y.

Cortisol release from adipose tissue by 11beta-hydroxysteroid dehydrogenase type 1 in humans.

Stimson R, Andersson J, Andrew R, Redhead D, Karpe F, Hayes P Diabetes. 2008; 58(1):46-53.

PMID: 18852329 PMC: 2606892. DOI: 10.2337/db08-0969.

Cortisol clearance and associations with insulin sensitivity, body fat and fatty liver in middle-aged men.

Holt H, Wild S, Postle A, Zhang J, Koster G, Umpleby M Diabetologia. 2007; 50(5):1024-32.

PMID: 17370058 DOI: 10.1007/s00125-007-0629-9.

Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 in obesity.

Wake D, Walker B Endocrine. 2006; 29(1):101-8.

PMID: 16622297 DOI: 10.1385/ENDO:29:1:101.

References

Masuzaki H, Flier J . Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome. Curr Drug Targets Immune Endocr Metabol Disord. 2003; 3(4):255-62. DOI: 10.2174/1568008033340135. View

EATON R, Allen R, Schade D, Erickson K, Standefer J . Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behavior. J Clin Endocrinol Metab. 1980; 51(3):520-8. DOI: 10.1210/jcem-51-3-520. View

Lindsay R, Wake D, Nair S, Bunt J, Livingstone D, Permana P . Subcutaneous adipose 11 beta-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. J Clin Endocrinol Metab. 2003; 88(6):2738-44. DOI: 10.1210/jc.2002-030017. View

Homma M, Tanaka A, Hino K, Takamura H, Hirano T, Oka K . Assessing systemic 11beta-hydroxysteroid dehydrogenase with serum cortisone/cortisol ratios in healthy subjects and patients with diabetes mellitus and chronic renal failure. Metabolism. 2001; 50(7):801-4. DOI: 10.1053/meta.2001.24213. View

Marin P, Darin N, Amemiya T, Andersson B, Jern S, Bjorntorp P . Cortisol secretion in relation to body fat distribution in obese premenopausal women. Metabolism. 1992; 41(8):882-6. DOI: 10.1016/0026-0495(92)90171-6. View

Bujalska I, Kumar S, Stewart P . Does central obesity reflect "Cushing's disease of the omentum"?. Lancet. 1997; 349(9060):1210-3. DOI: 10.1016/S0140-6736(96)11222-8. View

Walker B, Connacher A, Lindsay R, Webb D, Edwards C . Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J Clin Endocrinol Metab. 1995; 80(11):3155-9. DOI: 10.1210/jcem.80.11.7593419. View

Morton N, Holmes M, Fievet C, Staels B, Tailleux A, Mullins J . Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem. 2001; 276(44):41293-300. DOI: 10.1074/jbc.M103676200. View

Hauner H, Entenmann G, Wabitsch M, Gaillard D, Ailhaud G, Negrel R . Promoting effect of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium. J Clin Invest. 1989; 84(5):1663-70. PMC: 304034. DOI: 10.1172/JCI114345. View

10.

Wajchenberg B, Giannella-Neto D, Da Silva M, Santos R . Depot-specific hormonal characteristics of subcutaneous and visceral adipose tissue and their relation to the metabolic syndrome. Horm Metab Res. 2003; 34(11-12):616-21. DOI: 10.1055/s-2002-38256. View

11.

Livingstone D, Walker B . Is 11beta-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats. J Pharmacol Exp Ther. 2003; 305(1):167-72. DOI: 10.1124/jpet.102.044842. View

12.

Walker B, Seckl J . 11beta-hydroxysteroid dehydrogenase type 1 as a novel therapeutic target in metabolic and neurodegenerative disease. Expert Opin Ther Targets. 2003; 7(6):771-83. DOI: 10.1517/14728222.7.6.771. View

13.

Stewart P . Tissue-specific Cushing's syndrome, 11beta-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action. Eur J Endocrinol. 2003; 149(3):163-8. DOI: 10.1530/eje.0.1490163. View

14.

Wake D, Rask E, Livingstone D, Soderberg S, Olsson T, Walker B . Local and systemic impact of transcriptional up-regulation of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. J Clin Endocrinol Metab. 2003; 88(8):3983-8. DOI: 10.1210/jc.2003-030286. View

15.

Masuzaki H, Paterson J, Shinyama H, Morton N, Mullins J, Seckl J . A transgenic model of visceral obesity and the metabolic syndrome. Science. 2001; 294(5549):2166-70. DOI: 10.1126/science.1066285. View

16.

Seckl J, Walker B . Minireview: 11beta-hydroxysteroid dehydrogenase type 1- a tissue-specific amplifier of glucocorticoid action. Endocrinology. 2001; 142(4):1371-6. DOI: 10.1210/endo.142.4.8114. View

17.

Paulmyer-Lacroix O, Boullu S, Oliver C, Alessi M, Grino M . Expression of the mRNA coding for 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study. J Clin Endocrinol Metab. 2002; 87(6):2701-5. DOI: 10.1210/jcem.87.6.8614. View

18.

Andrews R, Rooyackers O, Walker B . Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab. 2003; 88(1):285-91. DOI: 10.1210/jc.2002-021194. View